anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a complex disorder with an unknown cause. However, the dysbiosis of the gut microbiome has been found to play a role in IBD etiology, including exacerbated immune responses and defective intestinal barrier integrity. The gut microbiome can also be a potential biomarker for several diseases, including IBD. Currently, conventional treatments targeting pro-inflammatory cytokines and pathways in IBD-associated dysbiosis do not yield effective results. Other therapies that directly target the dysbiotic microbiome for effective outcomes are emerging. We review the role of the gut microbiome in health and IBD and its potential as a diagnostic, prognostic, and therapeutic target for IBD. This review also explores emerging therapeutic advancements that target gut microbiome-associated alterations in IBD, such as nanoparticle or encapsulation delivery, fecal microbiota transplantation, nutritional therapies, microbiome/probiotic engineering, phage therapy, mesenchymal stem cells (MSCs), gut proteins, and herbal formulas.
The onset of action with betaxolol can generally be noted within 30 minutes and the maximum effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in IOP. In some patients, the IOP lowering responses to BETOPTIC S may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised.

Ophthalmic betaxolol solution at 1% (one drop in each eye) was compared to placebo in a crossover study challenging nine patients with reactive airway disease. Betaxolol HCl had no significant effect on pulmonary function as measured by forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, and was not significantly different from placebo. The action of isoproterenol, a beta stimulant, administered at the end of the study was not inhibited by ophthalmic betaxolol.

No evidence of cardiovascular beta-adrenergic blockade during exercise was observed with betaxolol in a double-masked, crossover study in 24 normal subjects comparing ophthalmic betaxolol and placebo for effects on blood pressure and heart rate.
Patients who are randomised to the 24 Hour Holter monitoring will be contacted within one month from randomisation. The repeat 24 Hour Holter result will be explained to the patient at the end of 30-day follow-up.
PURPOSE:To obtain the titled powdery cosmetic without irregular color and drying as well as cracking, by blending powder with an organic bentonite and/or ethyl cellulose and volatile solvent to form a slurry substance, spraying the resultant slurry into a thin film form on a board and drying the formed thin film. CONSTITUTION:Powder, e.g. extender pigment, organic coloring matter, inorganic pigment, metallic soap, pearling agent, mica, etc., is blended with an organic bentonite, e.g. stearyldimethylbenzylammonium hectorite, etc., as a binder and/or ethyl cellulose and a volatile solvent, e.g. trichlorotrifluoroethane, etc., to provide a slurry substance, which is the sprayed into a thin film form on a board, e.g. pulp paper, sheet made of a synthetic resin, etc.) and then dried to adhere the thin filmlike cosmetic to the board and afford the aimed thin filmlike powdery cosmetic.
Cardiovascular disease (CVD) is the most important cause of death of chronic kidney disease (CKD) and hemodialysis (HD) patients. Low Density Lipoprotein (LDL) is an essential indicator of CVD.The higher the plasma LDL level, the higher the risk of CVD. LDL is a heterogenous substance composed of different mass and size. Oxidized LDL (oxLDL) is the oxidation product of LDL and is the most important component of LDL associated with CVD. The oxLDL is mostly trapped within tissue and not easily to be detected from blood. L5 iw a kind of electronegative LDL and is associated with CVD in smokers and diabetic patients, even if these patients have normal plasma LDL. Uremia patients have lipid profile different from that of general people,while HD Patients have lower LDL and CKD patients have LDL higher than that of general population. Thus LDL plasma level cannot fully explain the high risk of CVD in CKD and HD patients. As patients with normal LDL but high L5 are prone to have CVD, we suspect there might be association of L5 with CVD in both CKD and HD patients.
In our aging society, dysphagia and malnutrition are growing concerns, necessitating intervention. Liquid nutrition support offers a practical solution for traditional dietary issues, but it raises a key issue: the potential for post-meal glucose spikes impacting efficacy. This study examined the effects of supplementation of Polygonatum cyrtonema Hua polysaccharide (PCP), konjac glucomannan (KGM) and their combination on acute phase postprandial glycemic response and long-term glucose metabolism in T2DM mice on a complete nutritional liquid diet. KGM was more effective in reducing postprandial glucose response, while PCP was more prominent in ameliorating long-term glucose metabolism. The KGM-PCP combination demonstrated superior outcomes in fasting blood glucose, insulin, and glucose homeostasis. PCP and KGM also influenced the composition and abundance of the gut microbiome, with the H-PCP group showing optimal performance. Moreover, the KGM-PCP combination improved body weight, lipid homeostasis, and liver health the most. PCP potentially regulates glycemia through metabolic pathways, while KGM improves glycemic metabolism by reducing postprandial glucose levels in response to viscous intestinal contents. This research identifies the structure, viscosity properties, and hypoglycemic effects of KGM and PCP in complete nutritional liquid diet fed T2DM mice, enabling their strategic utilization as hypoglycemic components in nutritional administration and glycemic regulation.
The invention relates to the quality control field of traditional Chinese medicine, in particular to a quality detection method of an anti-inflammatory and cholagogic preparation and applications thereof. The method comprises the steps of: establishing a standard fingerprint, establishing a fingerprint of a sample and comparing the standard fingerprint with the fingerprint of the sample. The standard fingerprint of the compound anti-inflammatory and cholagogic preparation shows 15 main chromatographic peaks in 225nm and confirms the chemical structures of 8 chromatographic peaks in the 15 main chromatographic peaks. The active ingredients with anti-inflammatory effect of three ingredients comprising andrographolide, rosemarinic acid and nigakinone in the 8 chemical structures are further confirmed. As the supplementation of the method, the three ingredients or the combination of the three ingredients can be indicative ingredients used for carrying content measurement. The methodhas high repeatability, good stability and simple and convenient operating method, is scientific with evidences and can effectively control the quality of the compound anti-inflammatory and cholagogic preparation.
Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 viral particle (VP) ,5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
After approval by the ethics committee of the patients Faculty of Dentistry, University of São Paulo that having root canal filling of primary teeth will be invited to participate in the study. A clinical examination and prior radiographic diagnosis will be-held. The patient will be randomized to one of two groups and will be made the endodontics by a dentist. The patient will be accompanied with periods of one week, one month and three months by a blinded evaluator. The outcome will be the success or failure of endodontic treatments evaluated through permanent tooth in the arch on clinical and radiographic conditions of normality. The longevity of the treatments will be evaluated by estimating survival rates by Kaplan-Meier. The differences between the survival rates according to the type of proposed endodontic treatment will be analyzed using the log-rank test with a minimum significance level of 5%.
PURPOSE:To obtain a skin external preparation. having stable and excellent effects on improvement of chapped skin, prevention of aging of skin, etc., by containing extract of a rosaceous plant and a superoxide dissmutase. CONSTITUTION:The objective skin external preparation contains one or two or more kinds of substances selected from extracts of rosaceous plant such as dried flower bud of Rosa rugosa var. plena Regel, dried seed of Prunus japonica Thunb. and dried fruit of Chaenomeles lagenaria Koidz. in an amount of 0.0001-10wt.% based on dried solid content and superoxide dissmutase which is a superoxide-removing enzyme distributed in living organisms such as animals, plants, microorganisms in an amount of 0.0001-5wt.% based on dried solid content, respectively. This preparation can be formulated as lotion, cream, cosmetic water, cleansing cream, pack, cleansing agent, foundation, etc., skin external preparation for dispersion type, granular or ointment-like medicine, quasi-drug and cosmetic. The preparation has an active oxygen removing action and extremely high preventing effects on production of lipoperoxide which results from production of active oxygen in the skin due to ultraviolet rays, inflammation, blackening, aging, etc.
In the long protocol, daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low E2 \< 50 and LH \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 FSH,AMH and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days according to the ovarian response to treatment starting on treatment cycle day for folliculometry and endometrial thickness and pattern.
The invention provides a restoring-type near infrared fluorescence probe with pH response. The chemical structural formula is shown as a formula (I) in the specification, wherein X refers to C(CH3)2, O, S or Se, Y refers to halogen, Z refers to NH, O or S, R1 and R2 are respectively independently selected from H, C1-18 alkyl or SO3R5, R5 refers to C1-18 alkyl or benzyl, and R3 and R4 are respectively independently selected from C1-18 alkyl or benzyl. When the restoring-type near infrared fluorescence probe with pH response is between pH 5.0 and pH 7.5, the fluorescence intensity is gradually enhanced along with reduction of the pH value, and an excellent linear relation is formed between the fluorescence intensity and the pH value. The stocks displacement is large, the signal to noise ratio is low, the toxicity is low, the damage to cells and living bodies is small, the pKa is 6.4, the probe is very suitable for tumor detection, and the defects of fluorescence probes in the prior art are overcome. The invention also provides a method for preparing the probe. The preparation method is simple.
Cells, preferably isolated pancreatic islet cells, are treated with a compound or a combination of compounds selected from an antioxidant, an anti-cytokine, an anti-endotoxin and an antibiotic. The compound or combination of compounds is in a medium for culturing the cells before microencapsulation, in a medium for cryopreserving the cells by freezing followed by thawing and microencapsulation, in a medium for culturing the cells after microencapsulation, or in a medium for culturing the cells before microencapsulation and in a medium for culturing the cells after microencapsulation. Microcapsules containing cells may be incubated with a physiologically acceptable salt to increase durability of the microcapsules. In a preferred method, isolated pancreatic islet cells are cultured for about 12 to about 36 hours in a medium containing an antioxidant as the compound, cryopreserved by freezing in a medium containing the compound or combination of compounds, thawed and microencapsulated. The microcapsule contains a hydrogel core such gelled alginate and a semipermeable outer membrane such as formed with polylysine. Encapsulated pancreatic islet cells are provided for transplantation that have enhanced glucose-stimulated insulin production.
Vincristine Sulfate Injection, USP is the salt of an alkaloid obtained from a common flowering herb, the periwinkle plant (Vinca rosea Linn). Originally known as leurocristine, it has also been referred to as LCR and VCR.

The molecular formula for Vincristine Sulfate, USP is C46H56N4O10∙H2SO4. It has a molecular weight of 923.04.

The structural formula is as follows:

Vincristine Sulfate, USP is a white to off–white powder. It is soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol. In 98% ethanol, Vincristine Sulfate, USP has an ultraviolet spectrum with maxima at 221 nm (ϵ+47,100).

Vincristine Sulfate Injection, USP is a sterile, preservative–free, single-dose only solution available for intravenous use in 1 mg/mL and 2 mg/2 mL (1 mg/mL) vials. Each mL contains 1 mg Vincristine Sulfate, USP, 100 mg mannitol and Water for Injection, USP. Q.S. Sulfuric acid or sodium hydroxide have been added for pH control. The pH of Vincristine Sulfate Injection, USP ranges from 4.0 to 5.0. At the time of manufacture, the air in the containers is replaced by nitrogen.
The role of eosinophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease (COPD) remains ambiguous and likely differs from its role in asthma. The molecular processes underlying the differences between eosinophils from asthma and COPD have not been sufficiently studied. The objective of this study was to compare the transcriptomic profiles of blood eosinophils in COPD and asthma. Eosinophils were isolated from peripheral blood drawn from stable mild-to-moderate COPD and asthma patients. RNA was isolated from eosinophils and sequenced using an NGSelect RNA. The prepared libraries were sequenced on an Illumina platform. The study group included five patients with asthma and four patients with COPD. The RNA-Seq data analysis identified 26 differentially expressed genes between COPD and asthma (according to adjusted p-value). In total, 6 genes were upregulated (e.g. CCL3L1, CCL4L2, GPR82) and 20 were downregulated (e.g. JUN, IFITM3, DUSP1, GNG7) in peripheral eosinophils of COPD patients compared to asthma. The genes associated with signalling of IL-4 and IL-13 pathways were downregulated in COPD eosinophils compared to asthma. In conclusion, blood eosinophils from COPD and asthma patients present different transcriptomic profiles suggesting their different function in pathobiology of both obstructive airway diseases. These differences might indicate the direction of the search of targeted therapy in COPD.
The invention relates to an RBBP4 targeting polypeptide, an anti-tumor polypeptide and application thereof. The amino acid sequence of the RBBP4 targeting polypeptide is shown as SEQ ID NO. 2. The anti-tumor polypeptide comprises an RBBP4 targeting domain and a transmembrane domain, and the amino acid sequence of the RBBP4 targeting domain is shown as SEQ ID NO. 2. The transmembrane domain of the anti-tumor polypeptide has no cytotoxicity, but has obvious effects of inhibiting tumor proliferation and migration invasion after being connected with the RBBP4 targeting domain. The antitumor polypeptide can be used as an antitumor biotherapeutic alone, and is expected to be combined with other treatment modes to inhibit tumors.
The utility model provides a corn convenience patch, which is a medical patch used for curing the corn. The utility model solves the problems in the prior medical patch that the normal skin around the corn is easy to be affected; the glutinosity of the prior medical  patch is weak; the prior art is easy to move, so the medical effect is affected; the volume of the medical patch is overstaffed, which affects the normal shoes wearing and walking and so on. The corn convenience patch of the utility model comprises a medicine layer patch, a medicament, a glue layer, a protective cushion layer and a medical transparent protective plastic layer. The medicament is placed at the center of one face of the medical layer patch; the glue layer is superposed on the medicament. A round hole is made at the center of the protective cushion layer; the glue layer is superposed on one face of the protective cushion layer. The protective cushion layer and the glue layer of the medical layer strap are respectively glued on the two faces of the medical transparent protective plastic layer. The utility model has the advantages that the glutinosity is strong; the utility model is not easy to move, so the medical effect is not affected; the medical patch is plane-shaped and is not overstaffed, so the normal shoes wearing and the walking are not affected and the use of the utility model is convenient.
At present, Magnetic Resonance Imaging (MRI) is widely used along with other tests to help diagnose dementia, however diagnosis still remains challenging. There is currently a focus on the usefulness of resting state functionalMRI (RS fMRI) as a way of establishing differences in functional connectivity between healthy subjects and those with various neurodegenerative disorders. Although the potential for RS fMRI to be used as a biomarker for neurological diseases looks promising, further research is needed, especially regarding validation of normal values and seed-based functional connectivity. Further research into this area will help to improve the ability to appropriately classify new subjects and ultimately allow use of RS functional connectivity as a biomarker. This is a nontreatment, prospective, natural history data collection that aims to analyse functional connectivity in a cohort of patients with suspected cognitive impairment. Correlation of global cognition and episodic memory performance to resting state fMRI functional connectivity will be evaluated. Patient population will include patients over the age of 18 with cognitive impairment and age and gender matched controls. Eligible patients will have to complete neuropsychological and clinical assessments and complete an fMRI scan prior to enrolment.Study duration is estimated at 4 years.
Non-traumatic subarachnoid hemorrhage (SAH) accounts for 3-5% of acute strokes. Intracranial aneurysm is the most common cause of non-traumatic SAH. Vitamin D influences the cardiovascular system, including the formation and rupture of cerebral aneurysms. To evaluate the serum vitamin D level in patients living in the tropical zone who suffered aneurysmal subarachnoid hemorrhage and its correlation with demographic and neurological characteristics. This is an analytical cross-sectional study to assess the serum level of vitamin D in a study population of 99 patients treated and diagnosed with aSAH in a public hospital in Recife-PE over a period of 12 months. In the study sample, composed of individuals with high sun exposure due to the lifestyle they lead in a tropical region, we observed hypovitaminosis D (85.9%), with a median of 19.9 ng/ml, although the majority of individuals are skin with high concentration of melanin (Fitzpatrick skin type IV and V). In addition, rates of sun exposure are high to all patients (Solar Index 9.03 P50). Most individuals were female (79.8%); there was no statistical difference in solar exposure/solar index between genders. As for the neurological repercussions, there was no statistical relevance in the clinical prognostic scales evaluated. As the sample was composed mainly of individuals whose economic activity is agriculture, the values of solar index found are vastly higher than those of other studies conducted in high latitude regions. In line with the literature review, some aspects were raised with the objective of justifying such findings that go from the base of the poor diet of these individuals, the increase of melanin in the skin and genetic alterations that directs us to possible mechanisms of natural photoprotection to high sun exposure. Thus, we had a vast majority (85%) of hypovitaminosis D, which in fact makes us wonder if there is any influence of calcitriol on vitamin D receptors in vascular walls and in the cardiovascular system as a whole, which influence bleeding events of this nature. As for the neurological repercussions, measured using assessment scales (Glasgow coma scale, WFNS scale, Hunt-Hess and Fisher's tomographic scale) there was no significant difference in the results. As it is only a descriptive study, the causal relationship of the facts cannot be established. However, in a population exposed to high sun exposure and affected by aneurysmal SAH, there is a significant rate of hypovitaminosis D, which supports the hypothesis that vitamin D plays a role in vascular pathologies, such as cerebral aneurysms and SAH.
PROBLEM TO BE SOLVED: To obtain a cosmetic such as rouge and pomade having transparency, imparting gloss in coating and having excellent spread, adhesion, gloss retentivity and preservation stability. SOLUTION: The objective solid cosmetic is obtained by mixing a dextrin fatty acid ester (e.g. dextrin palmitate), a heavy liquid isoparaffin and a liquid oily component (e.g. macadamia nut oil). Preferably, a mixing amount of each reagent in the mixing is respectively 5-15wt.% of the dextrin fatty acid ester, 30-50wt.% of the heavy liquid isoparaffin and 30-50wt.% of the liquid oily component. Preferably, the heavy liquid isoparaffin used is a liquid polymer copolymerized of isobutene with n-butene and having about 800-1,200 average molecular weight.